Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
ConditionNon Hodgkin Lymphoma
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorMiltenyi Biomedicine GmbH
About this trial
This is an observational long-term follow-up (LTFU) study for subjects who previously received zamtocabtagene autoleucel, known as MB-CART2019.1.
Eligibility criteria
Qualifiers
Received zamtocabtagene autoleucel in a Miltenyi Biomedicine-sponsored clinical study and have either completed the study or have discontinued early from the study.
Provided written informed consent to participate in this study.
Disqualifiers
None
Trial design
Treatments tested in this trial
- Long-term Follow-Up
Treatment groups
150 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov